J&J's TAR-200 drug fails a phase 3 bladder cancer trial, but the company is still confident in the blockbuster potential of the programme.

The Daily Tar Heel uses Twitter to connect with readers and share stories. We want to hear from you. If you want have photos, videos, an event you want to share with us, a question, or just want ...

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).